Tg Therapeutics (TGTX) EPS (Weighted Average and Diluted) (2020 - 2026)
Tg Therapeutics (TGTX) recorded quarterly EPS (Weighted Average and Diluted) of $0.12 in Q1 2026, down 20.0% quarter-over-quarter from $0.15 in Q4 2025, and up 300.0% on a YoY basis from $0.03 in Q1 2025.
Tg Therapeutics (TGTX) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Tg Therapeutics' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at $0.12 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 300.0% year-over-year to $0.12; the TTM figure through Mar 2026 stood at $2.87 (up 1095.83% YoY), while the FY2025 annual figure was $2.77, up 1746.67% from the prior year.
- EPS (Weighted Average and Diluted) was $0.12 for Q1 2026 at Tg Therapeutics, down from $0.15 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.43 in Q3 2025 to a low of -$0.57 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.08 across 5 years, with a median of $0.02 in 2024.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) tumbled 97.26% in 2024, then jumped 12050.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.57 in 2022, then jumped by 82.46% to -$0.1 in 2023, then surged by 250.0% to $0.15 in 2024, then slipped by 0.0% to $0.15 in 2025, then decreased by 20.0% to $0.12 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.12 (Q1 2026), $0.15 (Q4 2025), and $2.43 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn | 0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.12 |
| Dec 31, 2025 | 0.15 |
| Sep 30, 2025 | 2.43 |
| Jun 30, 2025 | 0.17 |
| Mar 31, 2025 | 0.03 |
| Dec 31, 2024 | 0.15 |
| Sep 30, 2024 | 0.02 |
| Jun 30, 2024 | 0.04 |
| Mar 31, 2024 | -0.07 |
| Dec 31, 2023 | -0.10 |
| Sep 30, 2023 | 0.73 |
| Jun 30, 2023 | -0.34 |
| Mar 31, 2023 | -0.28 |
| Dec 31, 2022 | -0.57 |
| Sep 30, 2022 | -0.26 |
| Jun 30, 2022 | -0.31 |
| Mar 31, 2022 | -0.52 |
| Dec 31, 2021 | -0.71 |
| Sep 30, 2021 | -0.65 |
| Jun 30, 2021 | -0.60 |